"2024 was transformative for OSE, marked by positive efficacy results, major partnerships, and accelerated preclinical ...

SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, ...

Actuate Therapeutics' elraglusib shows promise for pancreatic cancer, but financial instability and risks make it a high-risk ...